ArticleHistology and histopathology2025
The prognostic value of adipokine receptors leptinR and adiponectinR1 in obesity-inducible solid tumours.
Article in Histology and histopathology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundWith the rising incidence of life expectancy, obesity, and tumours, understanding the incretory influence of adipose tissue in tumorigenesis becomes increasingly important. As the adipokines leptin and adiponectin are released by fat tissue, we aimed to analyse the expression of their respective receptors in tumours for which an association with obesity is epidemiologically hypothesised.
methodsThe expression of leptinR and adipoR1 were analysed in cohorts of renal cell cancer (n=391), cervical cancer (n=155), vulvar cancer (n=107), and endometrial cancer (n=90) by immunohistochemistry and correlated with clinicopathological parameters including survival times.
resultsExpression of leptinR was high in renal cell cancer (62.2%), vulvar carcinoma (50%), and endometrial cancer (80.5%). High expression was associated with favourable clinicopathological markers and longer overall survival times in renal cell and vulvar cancer. AdipoR1 was only weakly expressed in all four tumour entities and did not show significant associations with clinicopathological parameters or prognosis.
conclusionHigh leptinR is a promising biomarker of favourable tumour outcomes in renal cell carcinoma and vulvar carcinoma.
Indexed as
Identifiers
40071541What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.